GPP
ZVRA icon

Great Point Partners’s Zevra Therapeutics ZVRA Stock Holding History

Great Point Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-347,824
Closed -$1.91M – 53
2023
Q1 		$1.91M Buy
+347,824
New +$1.84M 0.38% 36

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Great Point Partners's ZVRA Position: Q2 2023 in Review

Great Point Partners sold out of Zevra Therapeutics (ZVRA) in Q2 2023, closing a stake of 347,824 shares — an estimated $1.91M sold.

Great Point Partners first reported a position in ZVRA in Q1 2023 and held it in 1 quarter. The position peaked at $1.91M in Q1 2023. 71 funds tracked by Wall St. Rank hold ZVRA as of Q2 2023.

  • Great Point Partners reported no remaining Zevra Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Great Point Partners sold 347,824 Zevra Therapeutics shares in Q2 2023, an estimated $1.91M.
  • Great Point Partners first reported a position in Zevra Therapeutics in Q1 2023 and held it in 1 quarter.
  • Great Point Partners's Zevra Therapeutics position peaked at $1.91M in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2023.

Based on Great Point Partners's 13F filing for Q2 2023, filed 14 Aug 2023.